Mission Statement

Bioxytran is a clinical stage pharmaceutical company developing platform technologies in the fields of Glycovirology, Hypoxia and Degenerative Diseases to eliminate viruses and prolong lifespan using carbohydrate drug design.
Sign up for bioxytran updates


Glycovirology is a novel glycan-based platform technology.
Learn More

Degenerative Diseases

Bioxytran is developing an innovative platform of oxygen therapeutic treatments for hypoxic conditions and necrosis prevention.
Learn More

About BioxyTran Inc: Emerging Growth Highlight Reel


Glycovirology is a novel glycan-based platform technology. The concept behind it is that carbohydrate drugs can be used as entry inhibitors that attach directly to the binding domain of different viruses.  Our main drug candidate is designed to target the virus instead of the cell like most of the other compounds in development.  There is also evidence that carbohydrate drugs are capable of modulating the immune system.

Learn More

Hypoxia and Degenerative Diseases

Bioxytran is developing an innovative platform of oxygen therapeutic treatments for hypoxic conditions and necrosis prevention. Our initial targeted medical conditions are brain stroke, wound healing, and trauma. Most of these disease indications can use hyperbaric treatment, but it is costly and limited.  In these indications hyperbaric treatment shows promise, but the duration of treatment is limited due to oxygen toxicity our oxygen transport molecule has the ability to impact the duration of treatment due to its drug design.

Learn More


Bioxytran is developing two platform technologies in the fields of Glycovirology and Hypoxia and Degenerative Diseases. Learn more about our ProLectin & BXT pipelines here.

Learn More

Latest articles

Bioxtyran (OTCMKTS: BIXT) Licenses Phase 2 Asset for COVID-19 Patients After Finding Smoking Gun Journal Article
Mar 25, 2020

Bioxytran Inc. (OTCMKTS: BIXT) has a development stage hypoxia drug that that was initially targeting Acute Respiratory Distress Syndrome (ARDS) and stroke. Today they announced the licensing of a potentially phase 2 ready viral inhibitor which is designed to bind to a receptor on the protein spike of the virus.

BXT-25: A New Solution for Late Stage Treatment of Wuhan Coronavirus
Feb 13, 2020

Bioxytran Inc., a developmental stage biotechnology company with a pipeline of anti-necrosis drugs designed to treat hypoxia by delivering a nanoscale oxygen carrier to affected tissues in the lungs, brain, heart, and other vital organs offers a new and possibly life-saving treatment option for late-stage 2019-nCoV.

Scientific Background How cells sense and adapt to oxygen availability
Nov 8, 2019

The Nobel Prize in Physiology or Medicine for 2019 is awarded to William Kaelin, Jr., Sir Peter Ratcliffe, and Gregg Semenza. The need for oxygen to sustain life has been understood since the onset of modern biology; but the molecular mechanisms underlying how cells adapt to variations in oxygen supply were unknown until the prize-winning work described here. Animal cells undergo fundamental shifts in gene expression when there are changes in the oxygen levels around them. 

see all

Lorem Ipsum

Dr. Leslie Ajayi
CMO & Medical Advisory Board Chief
Dr. Ajayi brings over 20 years of clinical development experience in academia and industry. He is a fully trained physician leader with international specialty training in internal medicine, cardiovascular medicine, and clinical pharmacology. He received his undergraduate training in Health Sciences and his MD equivalent graduating Magna Cum Lade from Obafemi Awolowo University [OAU] in Nigeria. A few years later he received his PhD in clinical pharmacology from the University of Glasgow. As an academic clinical pharmacologist in Glasgow, UK, he worked with Big Pharma as an investigator for Phase 1 first in man, proof of concept, pharmacokinetics (PK), Pharmacodynamics (PD), PK-PD, and studies in special populations such as the elderly and in pregnancy. He was also involved in all types of designs of randomized controlled clinical trials (double blind, placebo controlled, double dummy, single blind, cross over, parallel group, Latin squares designs). His industry exposure was relegated to big pharma clinical research monitors and clinical research organizations. He worked on notable projects like perindopril and cilazapril (ACEI), and amlodipine. He evaluated the effects of ACEI on Type-2 Diabetes and insulin resistance in hypertensives.
Mike Sheikh
Chief Communication Officier
Ola Soderquist
Mr. Soderquist has more than 30 years of senior international entrepreneurial management experience within technology companies. He has served in CFO and other managerial capacities in multiple industry sectors and companies, such as Industrivarden (OMX:INDU), Electrolux (OMX:ELUX), Ericsson (NASDAQ:ERIC), Swedish Match (OMX:SWMA) and SKF AB (OMX:SKF), and most recently in Belden (NYSE: BDC) and Traction (OMX:TRAC).


Learn more about the team from BioxyTran


Learn more about BioxyTran investors and S1 Stocks


Join the conversation as we discuss Bioxytran's use-cases, development progress, and more.